The National Drug Policy for Malaria (2013) has been formulated with following objectives:
Accordingly, the ACT-Artemether + Lumefantrineis being used in seven North Eastern States in place of ACT-Artemether + Sulphadoxinepyremethamine. At remaining 12 centres, ACT (Artesunate+Sulphadoxinepyremethamine) in Pf cases as well as Chloroquine in Pvcases were found effective (cure rate nearly 100%).
- Reducing morbidity by prompt and complete treatment of suspected/confirmed malaria cases
- Prevention of progression of uncomplicated malaria into severe malaria and thereby reduce malaria mortality
- Prevention of relapses by administration of radical treatment
- Preventing transmission of malaria by use of gametocytocidal drugs
- Preventing development of drug resistance by rational treatment of malaria cases
- Treatment of uncomplicated P. falciparum cases: Complete course of three days Artemisinin based Combination Therapy (ACT) along with single dose of primaquine 0.75 mg/kg body weight on day 2.
- Treatment of uncomplicated P. vivaxcases:
Chloroquine – 10 mg/kg body weight on day 1 and day 2 and 5 mg/kg body weight on day Primaquine- 0.25 mg/kg body weight for 14 days. - For severe malaria cases (both Pv and Pf) injectableartemisinin derivatives followed by full course of ACT.
Accordingly, the ACT-Artemether + Lumefantrineis being used in seven North Eastern States in place of ACT-Artemether + Sulphadoxinepyremethamine. At remaining 12 centres, ACT (Artesunate+Sulphadoxinepyremethamine) in Pf cases as well as Chloroquine in Pvcases were found effective (cure rate nearly 100%).
Comments
Post a Comment